Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147

Alzheimer's Disease Clinical Trial

Official title:

A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147 in Healthy Young Volunteers and Healthy Elderly Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03838185
• Other study ID #: ABRJ147001
• Status: Completed
• Phase: Phase 1
• Start date: January 22, 2019
• Est. completion date: February 1, 2020

Study information

• Verified date: September 2020
• Source: Abrexa Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This Phase I clinical study is a randomized, double-blind, placebo-controlled, parallel-design study to thoroughly assess the safety profile and PK properties of J147 in healthy subjects. The study will include single ascending dose (SAD) in healthy young and elderly subjects.

Description:

This Phase I clinical study is a randomized, double-blind, placebo-controlled, parallel-design study to thoroughly assess the safety profile and PK properties of J147 in healthy subjects and to perform a preliminary assessment of the effect of food on safety and PK parameters of J147. The study will include single ascending dose (SAD) in healthy young and elderly subjects.

Approximately 64 subjects may be included in the study, with an additional 24 to be added depending on the emerging data.

Six cohorts of 8 healthy young male subjects and 2 cohorts of 8 healthy elderly male and female subjects are planned. Depending on emerging safety, tolerability and PK data, 2 additional cohorts of 8 healthy young male subjects in each cohort and 1 additional cohort of 8 elderly male and female subjects may be enrolled.

In each cohort, 6 subjects will be randomized to receive a single dose of J147 orally and 2 subjects will be randomized to receive a matching dose of placebo.

All cohorts will consist of 2 sentinel subjects of whom 1 subject will receive J147 and 1 subject will receive matching placebo. The remaining 6 subjects of whom 5 subjects will receive J147 and 1 subject will receive matching placebo will be dosed at least 24 hours following the sentinel subjects.

Healthy elderly subjects will receive doses that have been found to be safe in healthy young subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 64
• Est. completion date: February 1, 2020
• Est. primary completion date: February 1, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Provide voluntarily agreement to participate in this study and signs an IRB/IEC-approved informed consent prior to performing any of the screening procedures

• Healthy male subjects, between 18 to 50 years of age, inclusive, at the time of signing the informed consent; OR, Healthy male and female subjects, between 60 to 85 years of age, inclusive, at the time of signing the informed consent

• If male, subjects with partners of child bearing potential must be practicing abstinence, part of an abstinent life style or agree to use a highly effective contraception method during the intervention period and for at least 3 months after the last dose of study medication and refrain from donating sperm during this period. Because of the unacceptable failure rate of barrier (chemical and/or physical) methods, the barrier method of contraception must only be used in combination with a highly effective method. Post coital methods of contraception are not permitted.

• If female, must not be pregnant, must not be lactating, and must be of non-childbearing potential (surgically sterile [hysterectomy or bilateral tubal ligation] or postmenopausal = 1 year.

• Body mass index (BMI) between 18.0 and 30.0 kg/m2, inclusive, at screening with a weight of at least 50 kg

• Nonsmokers (or other nicotine use) as determined by history (no nicotine use over the past year) and by urine cotinine concentration (< 200 ng/mL) at the screening visit and admission

Exclusion Criteria:

• Has clinically significant history or evidence of cardiovascular, endocrine, hematologic, immune, gastrointestinal, genitourinary or other body system disease as determined by an Investigator

• Has clinically significant history or evidence of disease or dysfunction in neurological or psychiatric system that is likely to affect the results of the study in the opinion of an Investigator

• Has any disorder that would interfere with the absorption, distribution, metabolism or excretion of drugs

• Subject has any concurrent disease or condition that, in the opinion of the Principal Investigator, would make the subject unsuitable for participation in the clinical study

• Has positive test for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV) or human immunodeficiency virus (HIV) antibodies

• Has a urine blood test for ethanol or cotinine at the screening visit or admission

• Has a positive urine drug test (e.g., cocaine, amphetamines, barbiturates, opiates, benzodiazepines, cannabinoids) at the screening visit or admission

• Females who are breastfeeding

• Is unwilling to or has not avoided consumption of grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade or other products containing grapefruit or Seville oranges within 14 days of dosing with study medication

• Has history of alcohol and/or illicit drug abuse within 1 year of entry or is unwilling to avoid use of alcohol or alcohol-containing foods, medications or beverages, within 48 hours prior to admission until discharge from the clinical unit

• Has donated blood (> 500 mL) or blood products within 30 days prior to first day of dosing

• Requires treatment with any medication, prescription or over-the-counter (OTC) medications (including vitamins [mega doses], dietary supplements or herbal medications), prescription medications within 14 days prior to administration of study medication. By exception, acetaminophen = 1000 mg per day and vitamin products at recommended daily doses are permitted

• Has received any known hepatic or renal clearance altering agents (e.g., erythromycin, cimetidine, barbiturates, phenothiazines or herbal/plant-derived preparations such as St. John's wort) for a period of 30 days prior to dosing

• Has used an investigational drug within 30 days prior to screening

• Has a history of hypersensitivity or allergies to J147, any components of formulated J147, or any drug within the same class; minor drug allergies to a drug in another drug class may be approved by an Investigator if not considered of clinical relevance

• Has clinically significant abnormal vital signs, 12-lead ECGs, physical examination, clinical laboratory, or other safety variable, as judged by an Investigator

• Is considering or has scheduled any surgical procedure during study participation

• Requires a special diet or has a significant food allergy or intolerance; if the subject or patient is vegetarian, he or she may be enrolled at an Investigator's discretion

• Is unable to understand the protocol requirements, instructions and study related restrictions, the nature, scope and possible consequences of the clinical study

• Is unlikely to comply with the protocol requirements, instructions and study related restrictions; e.g., uncooperative attitude, inability to return for follow-up visits and improbability of completing the clinical study

• Has previously been enrolled in this clinical study or is currently enrolled in another clinical study

• For the elderly subjects, there must be no evidence of cognitive decline that has been greater than expected for age and no evidence of changes in their level of independence in everyday life.

• Is judged by an Investigator or Sponsor to be inappropriate for the study

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer's Disease

Intervention

Drug:
• J147
Single oral dose of J147
• Placebo
Single oral dose of corn oil

Locations

Country	Name	City	State
United States	Vince & Associates Clinical Research, Inc.	Overland Park	Kansas

Sponsors (2)

Lead Sponsor	Collaborator
Abrexa Pharmaceuticals, Inc.	Iqvia Pty Ltd

Country where clinical trial is conducted

United States, 

References & Publications (5)

Chen Q, Prior M, Dargusch R, Roberts A, Riek R, Eichmann C, Chiruta C, Akaishi T, Abe K, Maher P, Schubert D. A novel neurotrophic drug for cognitive enhancement and Alzheimer's disease. PLoS One. 2011;6(12):e27865. doi: 10.1371/journal.pone.0027865. Epub 2011 Dec 14. — View Citation

Currais A, Goldberg J, Farrokhi C, Chang M, Prior M, Dargusch R, Daugherty D, Armando A, Quehenberger O, Maher P, Schubert D. A comprehensive multiomics approach toward understanding the relationship between aging and dementia. Aging (Albany NY). 2015 Nov;7(11):937-55. — View Citation

Goldberg J, Currais A, Prior M, Fischer W, Chiruta C, Ratliff E, Daugherty D, Dargusch R, Finley K, Esparza-Moltó PB, Cuezva JM, Maher P, Petrascheck M, Schubert D. The mitochondrial ATP synthase is a shared drug target for aging and dementia. Aging Cell. 2018 Apr;17(2). doi: 10.1111/acel.12715. Epub 2018 Jan 7. — View Citation

Prior M, Dargusch R, Ehren JL, Chiruta C, Schubert D. The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice. Alzheimers Res Ther. 2013 May 14;5(3):25. doi: 10.1186/alzrt179. eCollection 2013. — View Citation

Prior M, Goldberg J, Chiruta C, Farrokhi C, Kopynets M, Roberts AJ, Schubert D. Selecting for neurogenic potential as an alternative for Alzheimer's disease drug discovery. Alzheimers Dement. 2016 Jun;12(6):678-86. doi: 10.1016/j.jalz.2016.03.016. Epub 2016 May 2. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of treatment-emergent adverse events	Nature, frequency and severity of adverse events	from pre-dose to 7+/-2 days post dose
Primary	Number of subjects with abnormal electrocardiogram	12-lead electrocardiogram measurement	from pre-dose to 7+/-2 days post dose
Primary	Incidence of clinically significant changes in serum biomarker levels in a standard serum chemistry panel	Changes in standard serum chemistry measures will be assessed.	from pre-dose to 7+/-2 days post dose
Primary	Incidence of clinically significant changes in hematological biomarker levels in a standard hematology panel	Changes in standard hematology measures will be assessed.	from pre-dose to 7+/-2 days post dose
Primary	Incidence of clinically significant changes in urine biomarker levels in a standard urinalysis panel	Changes in standard urinalysis measures will be assessed.	from pre-dose to 7+/-2 days post dose
Primary	Number of patients exhibiting changes in standard Physical Examination results		from pre-dose to 7+/-2 days post dose
Primary	Number of patients exhibiting changes in standard Neurological Examination results		from pre-dose to 7+/-2 days post dose
Secondary	Maximum plasma concentration (Cmax)		0-48 hours post dose
Secondary	Time to Cmax (Tmax)		0-48 hours post dose
Secondary	Area under the plasma concentration vs. time curve (AUC)		0-48 hours post dose
Secondary	Terminal rate constant		0-48 hours post dose
Secondary	Terminal half-life (t1/2)		0-48 hours post dose
Secondary	Apparent plasma clearance (CL/F)		0-48 hours post dose
Secondary	Renal clearance (CLr)		0-48 hours post dose